Logo

Benitec Receives Final Confirmation of Positive RAC Meeting

Jul 11, 2013
Premium

Benitec Biopharma announced last week that it has received a written report confirming a favorable review of a planned phase I/IIa clinical trial for its expressed hepatitis C treatment from the National Institutes of Health’s Recombinant DNA Advisory Committee.

The company said it made “minor” changes to the study’s protocol after meeting with the committee and has requested a pre-investigation new drug application hearing with the US Food and Drug Administration.

The company expects to begin the trial before the end of 2013.

In June, Benitec announced that its meeting with the RAC has been positive (GSN 6/13/2013).

Filed under

Gene Editing, Gene Silencing, & CRISPR
Infectious Disease
Recombinant DNA Advisory Committee
RNAi
expressed RNAi
Benitec
HCV
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.